Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System

NCT ID: NCT02607527

Last Updated: 2024-10-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-08
• Study Completion Date: 2019-12-19

Brief Summary

Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.

Detailed Description

Multi center evaluation of the Millipede IRIS for treatment of clinically significant mitral regurgitation in subjects determined appropriate for mitral valve surgery.

This trial is designed in accordance with the 2014 ACC/AHA guidelines for valvular heart disease, and the consensus statement of MVARC 2015.

Subjects will undergo transcatheter implantation of the Millipede IRIS implant.

Conditions

Mitral Valve Insufficiency

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

Device Implantation

Transcatheter IRIS placement

Group Type: OTHER

Mitral Valve IRIS Ring

Intervention Type: DEVICE

Transcatheter implantation of the IRIS

Interventions

Mitral Valve IRIS Ring

Transcatheter implantation of the IRIS

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Presence of symptomatic severe MR (effective regurgitant orifice (ERO) ≥0.2 cm2 for Secondary MR, ERO ≥0.4 cm2 for Primary MR)
• The New York Heart Association Functional Class II, III or ambulatory IV.
• Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50%
• Creatine Kinase-MB (CK-MB) obtained within prior 14 days < local laboratory -Upper Limit of Normal (ULN).

Exclusion Criteria

Presence of any of the following:

• Estimated pulmonary artery systolic pressure (PASP) > 70 mmHg assessed by site based on echocardiography or right heart catheterization
• Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
• Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)
• Hemodynamic instability requiring inotropic support or mechanical heart assistance.
• Hemodynamic instability defined as systolic pressure < 90 mmHg with or without afterload reduction, cardiogenic shock or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device.
• Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
• Coronary artery bypass grafting (CABG) within 30 days prior to subject's consent.
• Percutaneous coronary intervention within 30 days prior to subject's consent.
• Tricuspid valve disease requiring surgery.
• Aortic valve disease requiring surgery or TAVI.
• Carotid surgery within 30 days prior to subject registration.
• Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac -Resynchronization Therapy with cardioverter-defibrillator (CRT-D) within the last 30 days prior to subject registration.
• Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months.
• Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure.
• Status 1 heart transplant or prior orthotopic heart transplantation.
• Chronic Kidney Disease.
• Chronic Steroid Therapy.
• Cerebrovascular accident within 30 days prior to subject's consent.
• Severe symptomatic carotid stenosis (> 70% by ultrasound).Life expectancy < 12 months due to non-cardiac conditions.
• Active infections requiring current antibiotic therapy.
• Pregnant or planning pregnancy within next 12 months.
• Currently participating in an investigational drug or another device study.
• Severe organic lesions with mitral chords retraction, severely fibrotic and immobile leaflets, severely deformed subvalvular apparatus.
• endocarditis or active endocarditis in the last 3 months.
• Heavily calcified annulus or leaflets, mitral valve stenosis.
• Congenital malformation with limited valvular tissue
• Patient requires mitral valve replacement
• Previously implanted prosthetic mitral valve or annuloplasty ring/band.
• Evidence of LV or LA thrombus, vegetation or mass
• Left Ventricular Ejection Fraction <20%
• Left Ventricular End Diastolic Diameter >65 mm
• Severe tricuspid regurgitation or severe RV dysfunction
• Condition that prevents transatrial access or transfemoral access
• Anatomical ineligibility to the investigational device
• Known hypersensitivity or contraindication to procedural or post procedural medication (e.g., contrast solution, anticoagulation therapy) or hypersensitivity to nickel or titanium.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Scientific Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexandre Abizaid, MD

Role: PRINCIPAL_INVESTIGATOR

Dante Pazzanese de Cardiologia

Locations

Dante Pazzanese de Cardiologia

São Paulo, , Brazil

Sanatorio Italiano

Asunción, , Paraguay

Countries

Brazil; Paraguay

Other Identifiers

CP-002, CP-003

Identifier Type: -

Identifier Source: org_study_id